125 related articles for article (PubMed ID: 37915252)
1. Denosumab and Mortality in a Real-World Setting: A Comparative Study.
Alarkawi D; Tran T; Chen W; March LM; Blyth FM; Blank RD; Bliuc D; Center JR
J Bone Miner Res; 2023 Dec; 38(12):1757-1770. PubMed ID: 37915252
[TBL] [Abstract][Full Text] [Related]
2. Antiresorptive Medication Use Is not Associated With Acute Cardiovascular Risk: An Observational Study.
Bliuc D; Tran T; Chen W; Alarkawi D; Alajlouni DA; Blyth F; March L; Blank RD; Center JR
J Clin Endocrinol Metab; 2023 Apr; 108(5):e110-e119. PubMed ID: 36408625
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence.
Grassi G; Chiodini I; Palmieri S; Cairoli E; Arosio M; Eller-Vainicher C
Eur J Endocrinol; 2021 Aug; 185(3):387-396. PubMed ID: 34232124
[TBL] [Abstract][Full Text] [Related]
4. THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.
Anastasilakis AD; Polyzos SA; Makras P
Eur J Endocrinol; 2018 Jul; 179(1):R31-R45. PubMed ID: 29691303
[TBL] [Abstract][Full Text] [Related]
5. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates.
Uebelhart B; Rizzoli R; Ferrari SL
Osteoporos Int; 2017 Sep; 28(9):2701-2705. PubMed ID: 28540505
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment.
Kondo H; Okimoto N; Yoshioka T; Akahoshi S; Fuse Y; Ogawa T; Okazaki Y; Katae Y; Tsukamoto M; Yamanaka Y; Kawasaki M; Sakai A
J Bone Miner Metab; 2020 Nov; 38(6):894-902. PubMed ID: 32656645
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study.
Dito G; Lugaresi M; Degradi C; Guabello G; Longhi M; Corbetta S
Endocrine; 2023 Oct; 82(1):181-189. PubMed ID: 37402061
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis.
Ebina K; Hirao M; Hashimoto J; Hagihara K; Kashii M; Kitaguchi K; Matsuoka H; Iwahashi T; Chijimatsu R; Yoshikawa H
J Bone Miner Metab; 2018 Jul; 36(4):478-487. PubMed ID: 28766140
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Various Anti-Osteoporosis Drugs on All-Cause Mortality After Hip Fractures: A Nationwide Population Study.
Tai TW; Hwang JS; Li CC; Hsu JC; Chang CW; Wu CH
J Bone Miner Res; 2022 Aug; 37(8):1520-1526. PubMed ID: 35689432
[TBL] [Abstract][Full Text] [Related]
10. Treatment Effects of Bisphosphonates and Denosumab on Survival and Refracture from Real-World Data of Hip-Fractured Patients.
Behanova M; Reichardt B; Stamm TA; Zwerina J; Klaushofer K; Kocijan R
Calcif Tissue Int; 2019 Dec; 105(6):630-641. PubMed ID: 31531720
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Efficacy of Zoledronate Acid or Denosumab After Switching from Romosozumab in Japanese Postmenopausal Patients.
Oue T; Shimizu T; Asano T; Shimodan S; Ishizu H; Arita K; Iwasaki N
Calcif Tissue Int; 2023 Jun; 112(6):683-690. PubMed ID: 37037949
[TBL] [Abstract][Full Text] [Related]
12. Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases.
Burckhardt P; Faouzi M; Buclin T; Lamy O;
J Bone Miner Res; 2021 Sep; 36(9):1717-1728. PubMed ID: 34009703
[TBL] [Abstract][Full Text] [Related]
13. Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.
Bliuc D; Tran T; van Geel T; Adachi JD; Berger C; van den Bergh J; Eisman JA; Geusens P; Goltzman D; Hanley DA; Josse RG; Kaiser S; Kovacs CS; Langsetmo L; Prior JC; Nguyen TV; Center JR;
Osteoporos Int; 2019 Apr; 30(4):817-828. PubMed ID: 30607457
[TBL] [Abstract][Full Text] [Related]
14. Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses.
Cosman F; Huang S; McDermott M; Cummings SR
J Bone Miner Res; 2022 Nov; 37(11):2112-2120. PubMed ID: 36088628
[TBL] [Abstract][Full Text] [Related]
15. Denosumab or oral bisphosphonates in primary osteoporosis: a "real-life" study.
Cairoli E; Palmieri S; Goggi G; Roggero L; Arosio M; Chiodini I; Eller-Vainicher C
J Endocrinol Invest; 2018 Aug; 41(8):1005-1013. PubMed ID: 29340971
[TBL] [Abstract][Full Text] [Related]
16. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.
Anastasilakis AD; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Makras P
J Bone Miner Res; 2019 Dec; 34(12):2220-2228. PubMed ID: 31433518
[TBL] [Abstract][Full Text] [Related]
17. Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis.
Ebina K; Hirao M; Hashimoto J; Matsuoka H; Iwahashi T; Chijimatsu R; Etani Y; Okamura G; Miyama A; Yoshikawa H
Osteoporos Int; 2018 Jul; 29(7):1627-1636. PubMed ID: 29574517
[TBL] [Abstract][Full Text] [Related]
18. Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors.
Mazziotti G; Pedersini R; Vena W; Cosentini D; Carrone F; Pigni S; Simoncini EL; Torrisi R; Zambelli A; Farina D; Balzarini L; Lania AG; Berruti A
Calcif Tissue Int; 2022 Nov; 111(5):466-474. PubMed ID: 35902384
[TBL] [Abstract][Full Text] [Related]
19. Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis.
Ebina K; Hashimoto J; Kashii M; Hirao M; Miyama A; Nakaya H; Tsuji S; Takahi K; Tsuboi H; Okamura G; Etani Y; Takami K; Yoshikawa H
Mod Rheumatol; 2021 Mar; 31(2):485-492. PubMed ID: 32412351
[TBL] [Abstract][Full Text] [Related]
20. Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis.
Nakamura Y; Shimizu T; Asano T; Shimodan S; Ishizu H; Takahashi D; Takahata M; Iwasaki N
J Bone Miner Metab; 2021 Sep; 39(5):824-832. PubMed ID: 33821302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]